Equillium Inc. (EQ) — RQD Stock Rating Cockpit

$1.37 -3.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.36

Equillium Inc. (EQ) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $111.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EQ Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EQ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Equillium Inc. (NASDAQ: EQ) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.37 (-3.52% 1D, market cap $111.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EQ ranks #478 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EQ compare to ANIX and TLSA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EQ carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANIX (Anixa Biosciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $114.7M) and TLSA (Tiziana Life Sciences Ltd.) posts a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $115.1M). Among the 5-stock peer group, EQ leads on earnings multiple (N/A) while EQ leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EQ?
▼

Per EQ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001746466), Equillium Inc. generated $0 in revenue (-100.0% YoY), -$22.4M in net income, and -$22.8M in free cash flow against $31.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.36 (-0.82%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510042
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Cash (8)Whales (9)SEC (10)Macro (12)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7.3% Base Target
$4 Bull$1 Base$1 Bear
📬 FREE EQ RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EQ)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY EQ SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)

FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 43.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
50
Grade C-$1.41-15.6% Next Q
Q2 (-2Q)
47
Grade D$1.19+3.4% Next Q
Q3 (-1Q)
45
Grade D$1.23+11.4% Next Q
Current
42
Grade D-$1.37-7% Hist 90D α
Trajectory: C- (50) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EQ Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EQ currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.77) and Max Pain ($1.44) forces dealer call-delta covering toward $3.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EQ• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EQ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
43.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE22% OF RANGE
L: $1$1.37H: $4
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on EQ

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and -20.48% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (40)

12/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like EQ
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EQ)

  • ✓Walkthrough of EQ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
EQ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.84%▼ DESCENDING CHANNEL
2026-10-30O $1.38H $1.42L $1.29C $1.37VOL 310.6K
RES: $2.08SUP: $0.94SMA50: $1.77SMA200: $2.08
$3.71$3.02$2.33$1.64$0.95RES $2.08SUP $0.94$1.372026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EQ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EQ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EQ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EQ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EQ)

Health Care Rank #478 of 1016 ⚔️ ANIX vs EQ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EQ vs. ANIX, TLSA, NRXP, NERV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Equillium Inc. (EQ) ranks #478 by composite RQD confidence (42/100, grade D-) and #646 by equity capitalization ($111.3M). Within this direct 5-issuer industry benchmark cohort, EQ leads on earnings valuation at N/A trailing P/E, while EQ leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TLSA currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with EQ at 42/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EQ ACTIVE
Equillium Inc.
D- 42/100 — — -35.0% -3.52% $111.3M Benchmark Subject
ANIX
Anixa Biosciences Inc.
E 32/100 — — -35.0% -5.45% $114.7M /anix-vs-eq →
TLSA
Tiziana Life Sciences Ltd.
D+ 55/100 — — — -11.57% $115.1M /tlsa-vs-eq →
NRXP
NRX Pharmaceuticals Inc.
D- 36/100 — 58.8% -35.0% -14.66% $115.2M /nrxp-vs-eq →
NERV
Minerva Neurosciences Inc
D- 38/100 — — -35.0% +3.57% $107.0M /nerv-vs-eq →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001746466

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Equillium Inc. (EQ) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $41.1M , and -100.0% cumulative change since FY2023) , GAAP net income of -$22.4M, operating cash flow of -$22.7M, and free cash flow of -$22.8M (-19.3% YoY). On the balance sheet, EQ closed FY2025 with $31.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$22.4M -$22.7M -$22.8M $31.9M —
FY2024 (FY) 2024-12-31 $41.1M -$8.1M -$19.0M -$19.1M $25.6M —
FY2023 (FY) 2023-12-31 $36.1M -$13.3M -$21.8M -$21.8M — —

3. EQ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EQ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Equillium Inc. (NASDAQ: EQ) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.37 (-3.52% 1D, market cap $111.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EQ ranks #478 in composite RQD confidence.

How does EQ compare to ANIX and TLSA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EQ carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANIX (Anixa Biosciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $114.7M) and TLSA (Tiziana Life Sciences Ltd.) posts a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $115.1M). Among the 5-stock peer group, EQ leads on earnings multiple (N/A) while EQ leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EQ?

Per EQ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001746466), Equillium Inc. generated $0 in revenue (-100.0% YoY), -$22.4M in net income, and -$22.8M in free cash flow against $31.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EQ trading relative to its 50-day, 200-day, and 52-week technical levels?

EQ last traded at $1.37 (-3.52% on volume of 310,727 shares), positioning the stock -22.60% below its 50-day simple moving average ($1.77) and -34.13% below its 200-day simple moving average ($2.08). Across its 52-week range of $0.76 to $3.54, EQ sits at the 21.9% percentile with a 14-day RSI of 43.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.20 to $1.54).

EQ Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell EQ stock right now?

Equillium Inc. (EQ) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is EQ's 12-month price target and RQD AI Jury consensus?

EQ's 12-month base price target is $1.27 (range $0.99 to $3.72), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

EQ — Equillium Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:43:40Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, EQ scores 42 out of 100 with a letter grade of D- and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The fundamental cash engine pillar scores 8 out of 20, reflecting ROIC of -35% and an FCF yield of -20.48%; for a prospective investor, this means the business is currently consuming cash rather than generating it, so any valuation rests on future execution rather than present earnings power. The whale/13F flow pillar scores 9 out of 20 on institutional accumulation and options positioning, a modest signal that does not offset the weaker fundamentals. The insider conviction pillar scores 3 out of 20 on SEC Form 4 and Congressional PTR cluster flow, the lowest pillar, which signals limited insider-driven confidence in the source data. The macro regime fit pillar scores 12 out of 20 with a beta of 1.0 and sector sensitivity noted, indicating market-level volatility is roughly in line with the broad market. The forensic balance sheet pillar scores 10 out of 20, with an Altman Z-Score of 2.5, a Piotroski F-Score of 1 out of 9, and a Debt/Equity ratio of 0.5; the weak Piotroski reading is the most important red flag for an investor weighing the stock today. Upside drivers would require evidence of cash-flow inflection and improved forensic scores; the valuation tradeoff is that a market capitalization of $111.3M against negative cash generation leaves little margin of safety in the current framework.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-23.6M$-22.4MN/A$-22.8M$30.3MN/A
FY 2024$41.1M$-8.3M$-8.1MN/A$-19.1M$18.1MN/A
FY 2023$36.1M$-14.5M$-13.3MN/A$-21.8MN/AN/A

Per the market data, gross, operating, and net margins are each reported as 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1 out of 9, and the Debt/Equity ratio is 0.5. Reported operating losses persist across all three periods, and FY 2025 cash of $30.3M is the highest cash figure in the table, though the source does not provide a debt figure to assess net liquidity.

Open Questions

  • What are the company's products, commercial partners, and revenue model, given that FY 2025 revenue is reported as $0.0M?
  • What is the debt balance, since the debt field is N/A across all periods, and how does it affect net liquidity?
  • What drove the decline in revenue from $41.1M in FY 2024 to $0.0M in FY 2025?
  • What are the EPS figures, since EPS is N/A across all reported periods?
  • What institutional, insider, and options positioning exists, given that holder data is absent?

EQ Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Equillium Inc. (EQ) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EQ Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EQ Bull vs. Bear Conversation Board — What's Your Call at $1.37?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EQ 🐻 67% BEARISH CONVICTION
1. Pick Your Side on EQ:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.21 (-11.7%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is EQ (D- • RQD 42/100) a Buy at $1.37?

Welcome to the EQ (Equillium Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.05 (-23.4%)
Spot @ $1.37

Pump the brakes on EQ — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EQ, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Equillium Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.73 (+26.3%)
Spot @ $1.37

EQ cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EQ, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.37 (52-wk range $0.76 - $3.54), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%